title: Management of a patient with metastatic colorectal cancer and liver metastases.
abstract: Liver metastases are commonly encountered in patients presenting with metastatic colorectal cancer (mCRC); resection is the treatment of choice. A number of systemic treatment options are currently available for such patients, including the use of 5-fluorouracil-based chemotherapies and oxaliplatin (e.g., FOLFOX) in combination with biologic agents that target angiogenesis (e.g., bevacizumab). For patients with progression following first-line treatment, current second-line options include a change in chemotherapy with bevacizumab (for patients who did or did not receive prior bevacizumab) or FOLFIRI in combination with aflibercept, a more recently approved antiangiogenesis therapy. Neurotoxicity is a well-established adverse event of oxaliplatin-based therapy. The current case details an mCRC patient with liver metastases who was treated with a capecitabine and oxaliplatin regimen (XELOX), and experienced two episodes of transient cortical blindness possibly related to oxaliplatin. After disease progression, the patient was switched to a regimen of FOLFIRI and aflibercept and did well on this second-line regimen.
authors.affiliation: Tufts University School of Medicine, 800 Washington Street, Suite 7S-7099, Boston, MA 02111, USA.
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
references.citation: Gastrointest Cancer Res. 2009 Jul;3(4):134-40
references.pmid: 19742139
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2006-12
references.pmid: 18421053
references.citation: AJNR Am J Neuroradiol. 2003 Jun-Jul;24(6):1114-6
references.pmid: 12812935
references.citation: Ann Oncol. 2003;14 Suppl 2:ii13-6
references.pmid: 12810452
references.citation: J Clin Oncol. 2005 Aug 1;23(22):4853-5
references.pmid: 16051943
references.citation: Br J Cancer. 2011 Jun 28;105(1):58-64
references.pmid: 21673685
references.citation: Ann Oncol. 2010 May;21 Suppl 5:v93-7
references.pmid: 20555112
references.citation: Oncol Lett. 2012 Apr 1;3(4):831-838
references.pmid: 22741002
references.citation: J Clin Oncol. 2012 Oct 1;30(28):3499-506
references.pmid: 22949147
references.citation: Ann Surg. 2002 Oct;236(4):397-406; discussion 406-7
references.pmid: 12368667
references.citation: J Clin Oncol. 2008 Apr 20;26(12):2013-9
references.pmid: 18421054